Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma.

Abstract

Melanoma is the least common form of skin cancer and is associated with the highest mortality. Where melanoma is mostly unresponsive to conventional therapies (e.g., chemotherapy), BRAF inhibitor treatment has shown improved therapeutic outcomes. Photodynamic therapy (PDT) relies on a light-activated compound to produce death-inducing amounts of reactive oxygen species (ROS). Their capacity to selectively accumulate in tumor cells has been confirmed in melanoma treatment with some encouraging results. However, this treatment approach has not reached clinical fruition for melanoma due to major limitations associated with the development of resistance and subsequent side effects. These adverse effects might be bypassed by immunotherapy in the form of antibody-drug conjugates (ADCs) relying on the ability of monoclonal antibodies (mAbs) to target specific tumor-associated antigens (TAAs) and to be used as carriers to specifically deliver cytotoxic warheads into corresponding tumor cells. Of late, the continued refinement of ADC therapeutic efficacy has given rise to photoimmunotherapy (PIT) (a light-sensitive compound conjugated to mAbs), which by virtue of requiring light activation only exerts its toxic effect on light-irradiated cells. As such, this review aims to highlight the potential clinical benefits of various armed antibody-based immunotherapies, including PDT, as alternative approaches for the treatment of metastatic melanoma.

• Authors: Fleury Augustin Nsole Biteghe, Nyangone Ekome Toung Chalomie, Neelakshi Mungra, Guillaume Vignaux, Nan Gao, Aurelia Vergeade, Ambrose Okem, Krupa Naran, Jean De La Croix Ndong, Stefan Barth
• Journal: Biomedicines (Biomedicines) Vol. 8 Issue 9 (Sep 03 2020) ISSN: 2227-9059 [Print] Switzerland
• PMID: 32899183 (Publication Type: Journal Article, Review)